Takeda Pharmaceutical Company Limited
TKPHF
$34.39
-$1.61-4.47%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.48% | -1.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.48% | -1.52% | |||
| Cost of Revenue | 1.00% | -3.24% | |||
| Gross Profit | 3.24% | -0.61% | |||
| SG&A Expenses | 6.72% | -2.96% | |||
| Depreciation & Amortization | -0.86% | -0.49% | |||
| Other Operating Expenses | 298.41% | 161.82% | |||
| Total Operating Expenses | 7.85% | 0.37% | |||
| Operating Income | -27.32% | -10.81% | |||
| Income Before Tax | 354.68% | -81.68% | |||
| Income Tax Expenses | -27.74% | 48.31% | |||
| Earnings from Continuing Operations | 946.24% | -109.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -24.93% | -95.83% | |||
| Net Income | 940.31% | -109.30% | |||
| EBIT | -27.32% | -10.81% | |||
| EBITDA | -13.81% | -5.61% | |||
| EPS Basic | 940.24% | -109.22% | |||
| Normalized Basic EPS | -15.32% | -18.19% | |||
| EPS Diluted | 926.23% | -109.36% | |||
| Normalized Diluted EPS | -16.71% | -16.95% | |||
| Average Basic Shares Outstanding | 0.08% | 0.81% | |||
| Average Diluted Shares Outstanding | 1.77% | -0.67% | |||
| Dividend Per Share | -100.00% | -- | |||
| Payout Ratio | 2.93% | -1.64% | |||